{
    "clinical_study": {
        "@rank": "87563", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give WF 10 (TCDO) to\n      patients with advanced HIV disease who cannot or will not take zidovudine, didanosine,\n      zalcitabine, or stavudine. This study also examines how TCDO affects the levels of HIV in\n      the body. TCDO is a solution delivered through a vein."
        }, 
        "brief_title": "A Study of WF 10 IV Solution in Patients With Advanced HIV Disease", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Approved drugs at a stabilized dose except those specifically excluded.\n\n          -  Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis.\n\n        Patients must have:\n\n          -  HIV positivity.\n\n          -  Absolute CD4 count < 200 cells/mm3.\n\n          -  Intolerance to or refusal to take AZT, ddI, ddC, or d4T.\n\n          -  No active opportunistic infection requiring ongoing therapy.\n\n          -  Life expectancy at least 3 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Neoplasm other than basal cell carcinoma of the skin.\n\n          -  Clinically significant cardiac disease.\n\n          -  Anemia.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Cytotoxic chemotherapy.\n\n          -  Corticosteroids.\n\n        Patients with the following prior conditions are excluded:\n\n        History of myocardial infarction or arrhythmias.\n\n        Prior Medication:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Any antiretroviral agent.\n\n          -  Interferon.\n\n          -  Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic\n             chemotherapy, or neutropenic or nephrotoxic drugs.\n\n        Excluded within 30 days prior to study entry:\n\n          -  Investigational drugs.\n\n        Prior Treatment:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Radiation therapy. Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002152", 
            "org_study_id": "222B", 
            "secondary_id": "WF10-94-US-002"
        }, 
        "intervention": {
            "intervention_name": "WF10", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Nashville Health Management Foundation / Vanderbilt Univ"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "citation": "Kahn JO, McGrath MS, Ching OM, Kuhne FW. A single center, phase 2 study evaluating the effects of WF10. Int Conf AIDS. 1998;12:349 (abstract no 22423)"
            }, 
            {
                "citation": "Busch HW, Christensen S, Reichelt D, Jahn S, Zidek W. Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no PB0245)"
            }, 
            {
                "PMID": "9717676", 
                "citation": "Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, K\u00fchne FW. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection. 1998 Jul-Aug;26(4):202-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002152"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxo Chemie GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Nashville Health Management Foundation / Vanderbilt Univ": "36.166 -86.784"
    }
}